Back to Archived News
Axela Receives Key Patent on Light Diffraction Based Assays and Opens U.S. Facility
Thursday, February 07, 2008
Patent Defines Leading Position in Development of Novel Protein Research and Diagnostic Tools
Toronto, Canada -- Axela Inc., a recognized innovator in protein interaction technology, today announced it has been issued patent number 7,314,749, "Method and apparatus for assay based on light diffraction" by the United States Patent and Trademark Office. This core patent augments over 150 other patents and applications which define the company as the leading provider of novel protein research and diagnostic tools based on diffractive optic measurements.
Additionally the company announced it has changed its name from Axela Biosensors Inc. to Axela Inc. to reflect the broad range of applications and markets served by its technology beyond traditional biosensing. Axela has established operations in a GMP/GLP facility in Foster City, California to accelerate the development of real time multiplex immunoassay kits for the dotLab™ System.
"The issuance of this patent further reinforces the strong intellectual property position Axela has established in the use of diffractive optics to significantly improve the performance of immunoassays in research and diagnostic applications," commented Rocky Ganske, Axela CEO. "Initial product offerings available through our partner VWR International are focused on accelerating the study of biomolecular interactions, optimizing protein expression and the rapid development of quantitative immunoassays for the research markets. Axela and its collaborators have already demonstrated the benefits of real-time measurements that extend the dynamic range of multiplex analysis and access unique diagnostic targets. This is reflected in our recent name change and the expansion of US operations to commercialize proprietary content and panels."
About Axela Inc.
Axela has developed a proprietary technology for real time protein detection, characterization and monitoring directly in biological samples. The company’s products provide life science and clinical researchers simple tools and reagents to study interactions, expand the utility of traditional immunoassays and access novel categories of diagnostic markers. Participating in the research market provides unique access to novel discoveries that form the basis of a growing content pipeline for future multiplex diagnostic offerings. Axela is a privately-held company with operations in Toronto and California whose major investor is VenGrowth Private Equity Partners Inc., one of Canada's premier private equity managers. For more information, please visit www.axela.com.
Back to Archived News